
**Abstract N°: 7344**

**Efficacy and Safety of Vunakizumab in Scalp Psoriasis :A Case Report of Three Patients**

Jie Chen[1]

[1]Gulin Traditional Chinese Medicine Hospital, Department of Dermatology, Gulin, China

**Introduction & Objectives:**

Scalp involvement occurs in 45%–80% of psoriasis patients, often serving as the initial disease manifestation. This area is notoriously challenging to treat and significantly impacts quality of life. Vunakizumab, a novel interleukin-17A inhibitor, demonstrated favorable efficacy and safety in phase III trials (NCT04839016). This report evaluates its real-world performance in two patients with severe scalp psoriasis.

**Materials & Methods:**

Three adult male patients with extensive scalp psoriasis received Vunakizumab subcutaneously (240 mg biweekly for 3 doses, followed by monthly maintenance). Assessments included Psoriasis Area and Severity Index (PASI), Psoriasis Scalp Severity Index (PSSI), Investigator Global Assessment (IGA), Body Surface Area (BSA) and Dermatology Life Quality Index (DLQI) at baseline and Week 8.

**Results:**

**Table: Clinical Outcomes Before and After Treatment**

| ***Parameter*** | ***Patient1 (Baseline → Week 8)*** | ***Patient 2 (Baseline → Week 8)*** | ***Patient 3 (Baseline → Week 8)*** |
|---|---|---|---|
| *PASI Score* | 44.2 → 0 | 28.5 → 0 | 3 → 0.2 |
| *PSSI Score* | 21 → 0 | 15 → 0 | 16 → 6 |
| *IGA Score* | 4 → 0 | 4 → 0 | 3 → 1 |
| *BSA (%)* | 80 → 0 | 50 → 0 | 2 → 1 |
| *DLQI Score* | 10 → 0 | 9 → 0 | 3 → 0 |

All patients nearly achieved complete clearance of scalp and body lesions by Week 8. PASI, PSSI, and DLQI scores of two patients (patient 1 and patient 2) normalized to 0, reflecting total resolution of symptoms and restored quality of life. PSSI score of patient 3 who once treated with Secukinumab also achieved significant improvement .No adverse events were reported during the observation period.

**Conclusion:**

Vunakizumab, an IL-17A inhibitor, demonstrated rapid and profound efficacy in three patients with severe scalp psoriasis, nearly achieving complete lesion clearance by 8 weeks. These findings align with phase III trial data, supporting its role as a potent therapeutic option for recalcitrant scalp involvement. Larger studies are warranted to confirm long-term safety and durability.